PRINCETON, N.J., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer
immunotherapies, today announced three poster presentations have been accepted by the Society for Immunotherapy of Cancer’s (SITC)
31st Annual Meeting & Associated Programs taking place from Nov. 9-13 at Gaylord National Hotel & Convention Center in National
Harbor, Md. The poster presentations showcase the potential of Advaxis’ Lm Technology™ immunotherapies for monotherapy and
combination therapy in difficult-to-treat cancers.
The poster presentations featuring Advaxis immunotherapies at SITC 2016 include:
- “AIM2CERV: a randomized Phase 3 study of adjuvant AXAL immunotherapy following chemoradiation in patients who have high-risk
locally advanced cervical cancer (HRLACC)”
- “A Phase 1/2 study of durvalumab alone or in combination with AXAL in recurrent/persistent or metastatic cervical or human
papillomavirus (HPV)+ squamous cell cancer of the head and neck (SCCHN): preliminary Phase 1 results”
- “Combination of Listeria-based human papillomavirus (HPV) E7 cancer vaccine (AXAL) with CD137 agonist antibody
provides an effective immunotherapy for HPV-positive tumors in a mouse model”
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer
immunotherapies based on its proprietary Lm Technology. The Lm Technology, using bioengineered
live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent
shown in preclinical studies to both generate cancer fighting T cells directed against cancer antigens and neutralize Tregs and
myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor
growth. Advaxis' lead Lm Technology immunotherapy, AXAL, targets human papillomavirus (HPV)-associated cancers and is
in clinical trials for three potential indications: Phase 3 in invasive cervical cancer, Phase 2 in head and neck cancer, and Phase
2 in anal cancer. The FDA has granted AXAL orphan drug designation for each of these three clinical settings, as well as Fast Track
designation for adjuvant therapy for HRLACC patients and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC
patients. AXAL has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the
European Medicines Agency's Committee for Advanced Therapies. Advaxis has two additional immunotherapy products: ADXS-PSA in
prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are
developing ADXS-NEO, a preclinical investigational cancer immunotherapy treatment designed to activate a patient's immune system to
respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans
to enter the clinic in 2017.
For additional information on Advaxis, visit http://www.advaxis.com/ and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to: statements regarding the
completion and timing of the offering of shares. These forward-looking statements are subject to a number of risks, including the
risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the
fiscal year ended October 31, 2015, which is available at http://www.sec.gov, as well as the risks identified or incorporated by reference in the
registration statement and the prospectus supplement relating to the offering. Advaxis undertakes no obligation to publicly release
the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue
reliance on any forward-looking statements.
CONTACTS:
Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.250.7515
Media Contact:
JPA Health Communications
David Connolly
dconnolly@jpa.com
617.945.9316
![Primary Logo](https://resource.globenewswire.com/Resource/Download/f0e6a917-1265-4d54-8598-b6d56f64010f?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=MTg0IzY1NDIxMzA=)